

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE  
STATEMENT

Docket Number:  
1662/61502

Application Number  
10/717,148

Filing Date  
November 18, 2003

Examiner  
To be assigned

Art Unit  
1615

Invention Title  
CRYSTALLIZATION METHOD FOR PURIFICATION OF  
CALCIPOTRIENE

Inventor(s)  
SCHWARTZ, et al.

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450 on:

Date: 5/17/04

Signature: Virginia Hargis

Sir:


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed.
3. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.

Dated: May 13<sup>th</sup> 2004

By: John B. Starr, Jr.

John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON  
One Broadway  
New York, New York 10004  
(212) 425-7200 (telephone)



**INFORMATION DISCLOSURE  
STATEMENT  
BY APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
1662/61502

SERIAL NO.  
10/717,148

APPLICANT  
SCHWARTZ et al.

FILING DATE  
November 18, 2003

GROUP  
1615

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	5,292,727 A	March 8, 1994	Godtfredsen			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 03 060094	July 24, 2003	Europe				

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		PCT International Search Report - PCT/US03/37138
		Martin J. Caverley, "Synthesis of MC 903, a biologically active vitamin D metabolite analogue", Tetrahedron, vol. 43, no. 20, 1987, pgs. 4609-4616.
		Caverley, M. J. and Bretting, C., "1-alpha-24S-dihydroxy-26, 27-cyclo-22-yne-vitamin D3: the side chain triple bond analogue of MC 903 (calcipotriol)", Bioorganic and Medicinal Chemistry Letters, vol. 3, n. 9, 1993, pgs. 1841-1844.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	